Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Official Title

Phase I, Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of Pharmacokinetic and Safety Similarities Between Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Brief Summary

      The trial was designed as a single-center, randomized, double-blind, single-dose parallel
      controlled phase I study to evaluate the similarity of pharmacokinetics and safety of
      Meperizumab injection and NUCALA® in healthy male volunteers.

      The plan is to enroll 88 healthy subjects. After signing the written informed consent
      voluntarily, the subjects will undergo a series of examinations and information collection to
      determine whether they meet the inclusion criteria. The qualified subjects will be randomized
      and administered. Biological samples were collected and safety checked before and after
      administration according to protocol requirements. Adverse events occurred during the trial
      were collected, and the combination of drug use and non-drug treatment were asked and
      recorded in detail.

      When the 90% confidence interval of geometric mean ratio of the main pharmacokinetic
      parameters of Meperizumab injection and NUCALA® was within the range of 80.00%-125.00%, it
      was proved that the pharmacokinetic characteristics of the two were similar.

Study Phase

Early Phase 1

Study Type


Primary Outcome

Peak concentration(Cmax)

Secondary Outcome

 The area under the curve extrapolating from zero to infinity(AUC0-∞)


Granulomatosis With Polyangiitis


Meperizumab injection

Study Arms / Comparison Groups

 Meperizumab injection
Description:  Subcutaneous injection of meperizumab once


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 2022

Completion Date

October 2022

Primary Completion Date

October 2022

Eligibility Criteria

        Inclusion Criteria:

          -  1 Before the study, the informed consent was signed and the content, process and
             possible adverse reactions of the test were fully understood;

          -  2 Able to complete the research according to the requirements of the test protocol;

          -  3 Male subjects aged 18-55 (18 and 55 included);

          -  4 Body weight ≥ 50 kg ≤90 kg, body mass index (BMI) ≥ 19 ≤ 26kg/m2;

          -  5 Health status: No mental disorders, no history of cardiovascular system, nervous
             system, respiratory system, digestive system, urinary system, endocrine system and
             metabolic abnormalities;

          -  6 Subjects had no pregnancy plans and voluntarily used effective contraception for at
             least 6 months from 2 weeks prior to self-medication to their last use of study

        Exclusion Criteria:

          -  1 Previous neuropsychiatric, respiratory, cardiovascular, digestive, hemolymph,
             hepatic and renal dysfunction, endocrine, skeletal and musculoskeletal disorders, or
             other diseases that the investigator judged might affect drug metabolism or safety;

          -  2 Known allergy to meperizumab or its excipients;

          -  3 Known history of allergic disease or allergy or history of asthma disease;

          -  4 Prior treatment with meperizumab or an IL-5 receptor inhibitor, or other antibody or
             protein drugs that target the IL-5 receptor;

          -  5 Who received any live viral vaccines within 2 months prior to infusion of the study
             drug, or who needed to be vaccinated between the screening period and the end of the
             study, who used the study drug within 12 months prior to administration of the study
             drug or planned to receive any monoclonal antibodies or biologic drugs within 12
             months after administration of the study drug;

          -  6 Patients who have unhealed wounds, ulcers or fractures, or who underwent major
             surgery within 3 months prior to infusion of the study drug, or who are expected to
             undergo major surgery within 2 months after study completion;

          -  7 Any prescription, over-the-counter, vitamin product or herbal medicine used in the 2
             weeks prior to taking the study drug;

          -  8 Abnormal and clinically significant examinations during screening period;

          -  9 Blood donation or significant blood loss within 3 months prior to taking the study
             drug (& GT; 450 ml);

          -  10 Participated in any drug clinical trials within 3 months prior to taking the study

          -  11 Those who smoked more than 5 cigarettes a day 3 months before the experiment;

          -  12 History of alcohol abuse (14 units of alcohol per week: 1 unit =360mL beer or 45mL
             40% spirits or 150mL wine);

          -  13 Those who are screened positive for drugs or have a history of drug abuse in the
             past five years or have used drugs in the three months prior to the test;

          -  14 Screening positive for hepatitis (including hepatitis B and C), acquired
             immunodeficiency syndrome(AIDS) and syphilis;

          -  15 The subject is unable to complete the test due to personal reasons;

          -  16 Conditions that other researchers consider inappropriate for inclusion




18 Years - 55 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, 0431-86177635, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study Sponsor

, , 

Verification Date

April 2022